Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Geographic atrophy secondary to age-related macular degeneration
11 evidence topics · 8 sources
Annual prevalence of geographic atrophy in U.S. Medicare Advantage enrollees aged 65 years and older
“The total number of patients in the denominator was 2,175,803 (2018); 2,445,163 (2019); 2,680,322 (2020); and 2,905,366 (2021). The annual prevalence of GA was 0.56% (2018), 0.55% (2019), 0.48% (2020), and 0.51% (2021).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of GA was highest among individuals classified as White race (annual range 0.61% to 0.71%) and among patients with GA aged 75 years and older (range 0.95% to 1.11%). The proportion of patients with GA with co-occurring wet AMD was 25.6% to 28.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy by age, race, and foveal involvement in U.S. Medicare Advantage claims
“The annual prevalence for GA without SFI was 0.21% to 0.25% across the assessment years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence for GA with SFI was 0.27% to 0.31% during the same period. The annual prevalence of GA also was estimated at the level of eyes, with bilateral GA prevalence between 0.24% and 0.29% and unilateral GA between 0.23% and 0.27% from 2018 to 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the individuals classified as Black race, annual prevalence ranged from 0.09% to 0.11%. The annual prevalence of GA was calculated for 2 age categories; it was higher among individuals aged 75 years and older (0.95% to 1.11%) compared with people aged younger than 75 years (0.15% to 0.18%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy in U.S. Medicare Advantage claims with a 24-month ascertainment window
“In the sensitivity analyses, including an additional 12 months for measuring prevalence, the annual prevalence of GA increased: 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lower prevalence of GA observed in claims data relative to other studies warrants careful consideration; coding practices likely will evolve with new GA therapies on the market.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated number of people in the United States with geographic atrophy
Late AMD in U.S. adults aged 40 years and older in 2019 (geographic atrophy and neovascular AMD combined)
“We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late AMD in U.S. adults aged 40 years and older in 2000 (geographic atrophy and neovascular AMD combined)
“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global pooled prevalence of geographic atrophy by ancestry
“Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy and number affected in Nordic countries
“Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of geographic atrophy in Asian populations
“The pooled overall prevalence of GA was 1.57 per 1000 persons (95% confidence interval [CI], 1.04-2.10), which was 3 times less than that of neovascular AMD of 5.20 per 1000 persons (95% CI, 3.97-6.43). Compared with those aged 50 to 59 years, the prevalence of GA increased from 0.34 per 1000 persons (95% CI, 0.07-0.62) to 2.90 per 1000 persons (95% CI, 1.55-4.25) in those aged ≥70 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Late AMD in Europe, 2013 to 2040 (geographic atrophy and neovascular AMD combined)
“Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%–5.0%) in those aged 55–59 years to 17.6% (95% CI 13.6%–21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%–0.3%) and 9.8% (95% CI 6.3%–13.3%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This model also displayed that the number of people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote